Clin2
NCT06803680Possibly a fitRecruiting

Study of BGB-B455 for advanced solid tumors

Advanced Solid TumorMetastatic Solid Tumor

Part of Cancer clinical trials.

This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
90 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have advanced or metastatic solid tumors that cannot be removed by surgery and have been treated before or cannot tolerate standard treatment.
  • You agree to provide a tumor sample to test for the CLDN6 marker.
  • You have at least one measurable tumor on scans.
  • You are in good physical condition (able to do daily activities with little or no help).
  • Your organs are working well enough for the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06625593Recruiting· Phase 1
Study of BG-C137 for advanced solid tumors

This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.

Los Angeles, California
NCT06223256Recruiting· Phase 1
NBL-028 for advanced solid tumors with CLDN6

This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.

Shijiazhuang, Hebei
NCT05981703Recruiting· Phase 1
Study of BGB-26808 alone or with tislelizumab for advanced solid tumors

This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.

Duarte, California
NCT07304128Recruiting· Phase 1
PLB-002 for advanced solid tumors study

This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.

Shanghai, Shanghai Municipality
NCT07226349Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.

Birmingham, Alabama
NCT06589596Recruiting· Phase 1
Study of BGB-58067 for advanced solid tumors

This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.

Los Alamitos, California

Hear when a new Advanced Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.